Technology ID
E-330-2013-0

Peptide Vaccines Against Group A Streptococci

Linked ID
TAB-2665
Inventors
Bernard Beall (CDC)
Edwin Ades (CDC)
George Carlone (CDC)
Jacquelyn Sampson (CDC)
Lead Inventors
Bernard Beall (CDC)
Co-Inventors
Edwin Ades (CDC)
George Carlone (CDC)
Jacquelyn Sampson (CDC)
Development Status
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)
Therapeutic Areas
Infectious Disease
ICs
CDC
Commercial Applications
  • Group A streptococci (GAS) vaccine
  • GAS therapeutics and diagnostics
  • Lab tools for exploring GAS
This invention relates to synthetic immunoreactive peptides, which are portions of the M proteins of the most prevalent Group A Streptococcus (GAS) serotypes in the United States. These peptides may be useful in development of a flexible, multivalent GAS vaccine. They can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies. Additionally, the peptides or isolated antibodies raised in response to the peptides may be useful for GAS diagnostics.
Competitive Advantages
  • Easily adaptable to kit form
  • Multivalent vaccine that can be tailored for protection against specific GAS serotypes affecting a particular population

Request More Info

Licensing Contact